SCHEMBL24331963

SCHEMBL24331963

CC(C)(C)OC(=O)c1c[nH]c(Br)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.39
GABRG2 P18507 3/20 0.39
GABRB3 P28472 3/20 0.39
GABRA3 P34903 3/20 0.39
GABRA2 P47869 3/20 0.39
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
SLC7A5 Q01650 1/20 0.35
ALDH1A1 P00352 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
NOTUM Q6P988 1/20 0.33
BAZ2B Q9UIF8 1/20 0.33
BAZ2A Q9UIF9 1/20 0.33
STAT3 P40763 2/20 0.32
ALOX15 P16050 1/20 0.32
GABRA5 P31644 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22289962 0.81 NOTUM (0.53) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL1156046 0.79 ALDH1A1 (0.46) CA12CA1CA2CA9CA14
SCHEMBL22289959 0.79 GABRA1 (0.39) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL31198014 0.76 NOTUM (0.43) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL568982 0.75 CA12 (0.50) GABRA1GABRA3CA12CA1CA2
SCHEMBL7058435 0.74 CA12 (0.47) GABRA1GABRG2GABRB3GABRA3GABRA2
Formic Acid SCHEMBL31187369 0.74 ALDH1A1 (0.42) CA12CA1CA2CA9CA14
SCHEMBL3070779 0.73 NOTUM (0.47) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL7595533 0.73 NOTUM (0.47) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL13437108 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509453-B2 BRM/BRG1 inhibitors and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-12-30 US disclosed
US-20220119378-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2022-04-21 US disclosed
US-20220119378-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509453-B2 BRM/BRG1 inhibitors and uses thereof SMARCC1, SMARCC2, SMARCA1 GABRA1 442/4885GABRG2 499/4885GABRB3 402/4885
US-20220119378-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB GABRA1 749/4885GABRG2 767/4885GABRB3 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.